249 related articles for article (PubMed ID: 31930460)
1. After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?
Sculpher M; Palmer S
Pharmacoeconomics; 2020 Mar; 38(3):247-257. PubMed ID: 31930460
[TBL] [Abstract][Full Text] [Related]
2. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
Williams I; McIver S; Moore D; Bryan S
Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
[TBL] [Abstract][Full Text] [Related]
3. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
Williams I; Bryan S; McIver S
J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
[TBL] [Abstract][Full Text] [Related]
4. Estimating 'costs' for cost-effectiveness analysis.
Miners A
Pharmacoeconomics; 2008; 26(9):745-51. PubMed ID: 18767895
[TBL] [Abstract][Full Text] [Related]
5. Patients' views of explicit rationing: what are the implications for health service decision-making?
Devlin N; Appleby J; Parkin D
J Health Serv Res Policy; 2003 Jul; 8(3):183-6. PubMed ID: 12869346
[TBL] [Abstract][Full Text] [Related]
6. The impact of the National Institute for Health Research Health Technology Assessment programme, 2003-13: a multimethod evaluation.
Guthrie S; Bienkowska-Gibbs T; Manville C; Pollitt A; Kirtley A; Wooding S
Health Technol Assess; 2015 Aug; 19(67):1-291. PubMed ID: 26307643
[TBL] [Abstract][Full Text] [Related]
7. Justice, Transparency and the Guiding Principles of the UK's National Institute for Health and Care Excellence.
Charlton V
Health Care Anal; 2022 Jun; 30(2):115-145. PubMed ID: 34750743
[TBL] [Abstract][Full Text] [Related]
8. DECISION-COMPONENTS OF NICE'S TECHNOLOGY APPRAISALS ASSESSMENT FRAMEWORK.
de Folter J; Trusheim M; Jonsson P; Garner S
Int J Technol Assess Health Care; 2018 Jan; 34(2):163-171. PubMed ID: 29633673
[TBL] [Abstract][Full Text] [Related]
9. Evidence and values: paying for end-of-life drugs in the British NHS.
Chalkidou K
Health Econ Policy Law; 2012 Oct; 7(4):393-409. PubMed ID: 23079299
[TBL] [Abstract][Full Text] [Related]
10. Who does the numbers? The role of third-party technology assessment to inform health systems' decision-making about the funding of health technologies.
Barbieri M; Hawkins N; Sculpher M
Value Health; 2009; 12(2):193-201. PubMed ID: 18700865
[TBL] [Abstract][Full Text] [Related]
11. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
[TBL] [Abstract][Full Text] [Related]
12. Views of Directors of Public Health about NICE Appraisal Guidance: results of a postal survey. National Institute for Clinical Excellence.
Davies E; Littlejohns P
J Public Health Med; 2002 Dec; 24(4):319-25. PubMed ID: 12546211
[TBL] [Abstract][Full Text] [Related]
13. Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?
Hashem F; Calnan MW; Brown PR
Health Expect; 2018 Feb; 21(1):128-137. PubMed ID: 28686809
[TBL] [Abstract][Full Text] [Related]
14. Does NICE apply the rule of rescue in its approach to highly specialised technologies?
Charlton V
J Med Ethics; 2022 Feb; 48(2):118-125. PubMed ID: 33685978
[TBL] [Abstract][Full Text] [Related]
15. NICE's use of cost effectiveness as an exemplar of a deliberative process.
Culyer AJ
Health Econ Policy Law; 2006 Jul; 1(Pt 3):299-318. PubMed ID: 18634698
[TBL] [Abstract][Full Text] [Related]
16. Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals.
Bryan S; Williams I; McIver S
Health Econ; 2007 Feb; 16(2):179-93. PubMed ID: 16960851
[TBL] [Abstract][Full Text] [Related]
17. NICE and Fair? Health Technology Assessment Policy Under the UK's National Institute for Health and Care Excellence, 1999-2018.
Charlton V
Health Care Anal; 2020 Sep; 28(3):193-227. PubMed ID: 31325000
[TBL] [Abstract][Full Text] [Related]
18. The cancer technology appraisal programme of the UK's National Institute for Clinical Excellence.
Littlejohns P; Barnett D; Longson C;
Lancet Oncol; 2003 Apr; 4(4):242-50. PubMed ID: 12681268
[TBL] [Abstract][Full Text] [Related]
19. Getting their say, or getting their way? Has participation strengthened the patient "voice" in the National Institute for Clinical Excellence?
Quennell P
J Manag Med; 2001; 15(3):202-19. PubMed ID: 11547580
[TBL] [Abstract][Full Text] [Related]
20. Modifying NICE's Approach to Equity Weighting.
Paulden M; McCabe C
Pharmacoeconomics; 2021 Feb; 39(2):147-160. PubMed ID: 33517512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
